Panna Sharma

Busting the Brain’s Firewall: How Lantern Pharma’s Algorithms Can Predict a Drug’s Ability to Reach the Brain

by | May 2, 2023
The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.
Lantern Pharma Adds VP of Clinical Development, Additional Team Members
by | Mar 2, 2023

Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members....

Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise
by | Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.

Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
Lantern Pharma CEO Shares His Four Secrets to Turning a Startup into an IPO
by | Aug 3, 2021
Panna Sharma has had a hand in four IPOs. The latest was finalized during the middle of COVID for his clinical stage biopharmaceutical oncology firm, Lantern Pharma. Now, he shares the phases to transforming a young private company into the next public success story.